Mass Tort brief
Mass Litigation Pressures Shift to City Valuations and UK Consumer Payouts
From Reckitt's stalled infant formula divestment to Mastercard's £100M payout, mass liability claims are driving corporate strategies and consumer recoveries.
Mass Tort
Reckitt's mounting US infant formula lawsuits are blocking strategic asset sales — leaving its London stock trading at a deep liability discount.
BackgroundParents of premature infants filed product liability lawsuits alleging specialized infant formula increases the risk of necrotizing enterocolitis. Earlier multi-million-dollar court verdicts against Mead Johnson and Abbott created severe, long-term liability fears across global health markets.
- Danone publicly confirmed it ended talks to buy Mead Johnson specifically to avoid inheriting unresolved 20-year liability risks, reported Consumer Notice.
- Reckitt faces multiple federal bellwether trials scheduled across 2026 and 2027 that will establish benchmark damages for hundreds of pending claims.
- City analysts warn that unresolved US mass tort litigation will continue to depress Reckitt's stock price and block major asset sales in London.
Mass Tort
Settlement of the Mastercard funding fight unblocks £100M for UK consumers — proving Britain's collective action legal framework can deliver massive mass-tort payouts.
BackgroundThe landmark collective action against Mastercard alleged illegal transaction fees inflated retail prices across the UK for 16 years. It stands as the largest collective legal proceeding in British history, pioneering the nation's opt-out class action framework.
- The tribunal approved £62.5M paid to litigation funder Innsworth out of court recoveries, ending years of legal deadlocks, reported The Global Legal Post.
- Merricks will launch a nationwide claim distribution program to deliver £100M directly to millions of eligible UK consumers who paid inflated card fees.
- The dispute resolution establishes essential judicial precedent for third-party litigation funding structures under current UK collective action law.
Mass Tort
An $88M verdict against Covidien exposes Medtronic to massive legal liabilities — forcing NHS suppliers and UK solicitors to reassess medical device risks.
BackgroundOver 2,400 product liability lawsuits are consolidated in federal multidistrict litigation alleging Covidien's surgical mesh resorbed prematurely and caused internal harm. Medtronic medical devices are deployed extensively across National Health Service hospitals.
- The jury awarded $77M to the injured plaintiff and $11M to his spouse after finding Covidien failed to warn doctors of degradation risks, reported SettLiT.
- The $88M outcome marks a critical valuation indicator that significantly raises settlement expectations for thousands of remaining plaintiffs in MDL 3029.
- UK product liability solicitors are evaluating device failure rates across NHS surgical implant registries to gauge potential domestic litigation exposure.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
